Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer
Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer
复制标题
ERβ和CD44表达对II期结肠癌患者预后的影响
DOI：
10.1007/s13277-012-0451-y
复制
发表时间：
2012-12-01
期刊：
影响因子：
--
通讯作者：
Wan, De-Sen
中科院分区：
文献类型：
--
作者：
Fang, Yu-Jing;Zhang, Lin;Wan, De-Sen
本研究探讨了ER β /CD44表达与II期结肠癌患者进展的相关性。方法采用免疫组化方法对1995 ~ 2003年的220例II期结肠癌石蜡包埋标本进行正常黏膜和肿瘤组织中ER β和CD44的检测。采用Kaplen-Meier法、log-rank检验和Cox比例风险回归模型对总生存数据进行分析。ROC曲线用于描述变量预测预后的能力。采用叠刀法对预测结果进行交叉验证。cd44高表达与低表达肿瘤组织患者的生存率分别为61%与90%，p < 0.0001； ER β高表达与低表达肿瘤组织患者的生存率分别为99%与36%，p < 0.0001。此外，ER β与CD44表达的相互作用发现，CD44对整体存活的影响仅在ER β表达较低时出现；ER β -肿瘤的高表达可视为总生存期的保护因素。本研究提示低表达ER β -tumor和高表达CD44-tumor是影响II期结肠癌患者总生存的危险因素。
The correlation of ER beta/CD44 expression and progression of patients with stage II of colon cancer were explored in this work. A total of 220 paraffin-embedded specimens with stage II colon cancer from 1995 to 2003 were included for assessing ER beta and CD44 by immunohistochemistry in normal mucosa and tumor tissues. Kaplen-Meier method, log-rank test, and the Cox proportional hazards regression model were used to analyze the overall survival data. ROC curve was used to describe the capacity of variables in prognosis prediction. Jackknife method was used to perform cross validation of predictions. The survival rates were significantly different between the patients with high expression and low expression of CD44-tumor tissues (61 % vs. 90 %, p < 0.0001) and between the patients with high expression and low expression of ER beta-tumor tissue (99 % vs. 36 %, p < 0.0001), respectively. In addition, the interaction between expression of ER beta and CD44 was found that the impact of CD44 to the overall survive appeared only when expression of ER beta was low; and the high expression of ER beta-tumor could be regarded as a protective factor for overall survival. This study suggest that low expression of ER beta-tumor and high expression of CD44-tumor are risk factors for overall survival in patients with stage II colon cancer.